156 related articles for article (PubMed ID: 10728718)
1. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?
Catts VS; Catts SV
Schizophr Res; 2000 Feb; 41(3):405-15. PubMed ID: 10728718
[TBL] [Abstract][Full Text] [Related]
2. Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies.
Ni X; Trakalo J; Valente J; Azevedo MH; Pato MT; Pato CN; Kennedy JL
Neurosci Lett; 2005 Nov; 388(3):173-8. PubMed ID: 16039051
[TBL] [Abstract][Full Text] [Related]
3. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?
Domchek SM; Bradbury A; Garber JE; Offit K; Robson ME
J Clin Oncol; 2013 Apr; 31(10):1267-70. PubMed ID: 23460708
[No Abstract] [Full Text] [Related]
4. Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits.
Papiol S; Arias B; Barrantes-Vidal N; Guitart M; Salgado P; Catalán R; Fañanás L
Neurosci Lett; 2004 Jun; 363(1):78-80. PubMed ID: 15158001
[TBL] [Abstract][Full Text] [Related]
5. [The importance of a SNiP of the MDM2 gene to modulate the p53 pathway and the predisposition to cancer].
Larsen CJ
Bull Cancer; 2011 Jan; 98(1):10. PubMed ID: 21591298
[No Abstract] [Full Text] [Related]
6. Association between polymorphisms in the genes for tumor suppressor protein p53 and its regulator NAD(P)H: quinone oxidoreductase 1 (NQO1) and schizophrenia in a Syrian study cohort.
Lajin B; Alachkar A; Michati R; Alhaj Sakur A
Arch Med Res; 2013 Feb; 44(2):121-6. PubMed ID: 23360829
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
8. Tumour suppression by p53: the importance of apoptosis and cellular senescence.
Zuckerman V; Wolyniec K; Sionov RV; Haupt S; Haupt Y
J Pathol; 2009 Sep; 219(1):3-15. PubMed ID: 19562738
[TBL] [Abstract][Full Text] [Related]
9. Mouse models with modified p53 sequences to study cancer and ageing.
Clarke AR; Hollstein M
Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
[TBL] [Abstract][Full Text] [Related]
10. [Apoptosis--programmed cell death].
Borner M
Ther Umsch; 1998 Jul; 55(7):459-61. PubMed ID: 9702120
[TBL] [Abstract][Full Text] [Related]
11. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
12. The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia.
Cui DH; Jiang KD; Jiang SD; Xu YF; Yao H
Mol Psychiatry; 2005 Jul; 10(7):669-77. PubMed ID: 15768050
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumour suppressor gene.
Steele RJ; Thompson AM; Hall PA; Lane DP
Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
[TBL] [Abstract][Full Text] [Related]
14. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
[TBL] [Abstract][Full Text] [Related]
15. Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis.
Kuhlmann T; Glas M; zum Bruch C; Mueller W; Weber A; Zipp F; Brück W
J Neuroimmunol; 2002 Aug; 129(1-2):154-60. PubMed ID: 12161031
[TBL] [Abstract][Full Text] [Related]
16. Revealing the intricacies of cancer.
Verhagen AM; Lock P
Genome Biol; 2002; 3(6):REPORTS4015. PubMed ID: 12093370
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility?
Coates PJ; Lorimore SA; Lindsay KJ; Wright EG
J Pathol; 2003 Nov; 201(3):377-88. PubMed ID: 14595749
[TBL] [Abstract][Full Text] [Related]
18. Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients.
Molina V; Papiol S; Sanz J; Rosa A; Arias B; Fatjó-Vilas M; Calama J; Hernández AI; Bécker J; Fañanás L
Neuroimage; 2011 May; 56(1):45-51. PubMed ID: 21296169
[TBL] [Abstract][Full Text] [Related]
19. The role of DNA damage responses in p53 biology.
Speidel D
Arch Toxicol; 2015 Apr; 89(4):501-17. PubMed ID: 25618545
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas.
Green VL; White MC; Hipkin LJ; Jeffreys RV; Foy PM; Atkin SL
Eur J Endocrinol; 1997 Apr; 136(4):382-7. PubMed ID: 9150697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
